Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1972 | Interleukin-1 receptor antagonist Wiki | 1.00 |
| drug291 | Angiotensin II Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A Phase I/II clinical trial for safety and efficacy evaluation of treatment with anti-SARS-CoV-2 equine immunoglobulin (F(ab')2) in hospitalized patients with COVID-19 not requiring of invasive ventilation support.
Description: Viral load reduction evaluated by area under the curve of RT-PCR values
Measure: Reduction of viral load evaluated by area under the curve of RT-PCR values Time: Day 0, Day 3, Day 7 and Day 14Description: number of days between admission and discharge
Measure: Length of hospital stay Time: For as long as the duration of the hospital stayDescription: Number of patients who progressed to the use of invasive mechanical ventilation and require orotracheal intubation throughout hospitalization
Measure: Orotracheal Intubation Rate Time: 28 daysDescription: number of patients who experienced adverse events after the immunoglobulin infusion
Measure: Infusional reaction rate Time: 28 daysDescription: number of deceased patients
Measure: Mortality rate Time: 28 daysDescription: Frequency of adverse events classified following CTCAE
Measure: Assessment of adverse events Time: 28 daysDescription: Results of a 7-point ordinal severity scale
Measure: Evaluation of clinical status Time: Day 0, Day 14, Day 21 and Day 28Description: Exploratory analysis of the variation of inflammatory markers by ELISA/Luminex and flow cytometry, compared to baseline levels
Measure: Modulation of serum and cellular inflammatory marker Time: Day 0, Day 3 and Day 7.Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports